GlycoNex Inc.

GlycoNex Inc. is a biotechnology company specializing in the development of innovative therapies for cancer and other diseases through the use of glycosphingolipid antigen and human monoclonal antibody technologies. Founded in 2001 and based in New Taipei City, Taiwan, the company is recognized as a pioneer in integrating glycotechnology with monoclonal antibody engineering within the Asian healthcare sector. Its core activities include the research and development of novel biologic entities (NBEs) and biosimilars, antibody engineering, cell line development, and advanced glycan analysis. GlycoNex’s development pipeline is focused on treatments for solid tumors, featuring lead candidates such as GNX102, currently in phase 1 clinical trials, along with several additional preclinical and early-stage antibody therapeutics targeting cancer and related indications. The company also develops specialty antibodies for research purposes and explores applications in osteoporosis and ophthalmology. By combining specialized glycobiology with therapeutic antibodies, GlycoNex Inc. aims to address critical unmet needs in oncology and allied biomedical fields, contributing significantly to the progress of precision medicine in the biotechnology industry.